Perioperative medicine & outcomes
Perioperative remimazolam administration to prevent delirium and neurocognitive disorders after surgery: a systematic review and meta-analysis
Pooled result · PODResult — go to the resultOdds ratio 0.79 95% CI 0.53–1.17Authors' conclusion
Our research indicates that remimazolam exhibits no superiority in preventing postoperative delirium.
Study context
- Population
- Patients undergoing surgery (randomized controlled trials (RCTs) and cohort studies of perioperative remimazolam)
- Participants
- 2,188 patients · 11 studies
- Comparison
- Remimazolam vs propofol or other sedative medical therapy
- Remimazolamn = 981
- Controln = 1,207reference
- Outcome
- Incidence of postoperative delirium (POD)
Pooled result
POD
Odds ratio
0.79
95% CI 0.53–1.17
P = 0.24
Remimazolam vs Control
OR 0.79 (95% CI 0.53–1.17); P = 0.24
As reported in the abstract
Safety
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| VomitingI2 = 0% | 1.35 (0.85–2.15) | P = 0.21 | |
| HypoxiaI2 = 76% | 0.59 (0.12–3.00) | P = 0.53 | |
| AgitationI2 = 62% | 0.48 (0.15–1.46) | P = 0.19 | |
| HypotensionI2 = 0% | 0.29 (0.20–0.42) | P < 0.001 | |
| BradycardiaI2 = 67% | 0.19 (0.05–0.76) | P = 0.03 | |
| 0.050.21520Odds ratio (log scale) |
Original publication
Perioperative remimazolam administration to prevent delirium and neurocognitive disorders after surgery: a systematic review and meta-analysis. Perioper Med (Lond). Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →